D2R News
Stay informed about D2R updates by subscribing to our mailing list!
Stay informed about D2R updates by subscribing to our mailing list!
On this page, you will find press releases, media coverage, newsletters, reports, and D2R Community news allowing you to follow D2R’s latest news. For all interview or information requests from media representatives, please contact D2R.comms [at] mcgill.ca.
D2R awards $400K to translate RNA research into real-world solutions (June 2025)
D2R awards $10 million to accelerate RNA-based therapies for rare diseases and cancer (March 2025)
McGill awards $500,000 to accelerate Mpox research and vaccine development (February 2025)
D2R awards over $6 million to support Core Platforms (February 2025)
D2R announces new round of funding, investing $1.5 million to advance research in RNA therapeutics and to support McGill Centres and Institutes (December 2024)
CQDM partners with D2R to enhance collaborations among researchers and industry in RNA research (November 2024)
Philippe Gros appointed Chief Scientific Officer of D2R (October 2024)
D2R welcomes RNA and genomic researchers to Université de Sherbrooke (October 2024)
Génome Québec invests up to $500,000 to boost RNA therapeutics innovation in Quebec (October 2024)
D2R awards $7.3 million to Advance Research in Genomic-Based RNA Therapeutics (September 2024)
$165-million for McGill University’s world-leading inclusive genomics and RNA research program (April 2023)